Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide.

Abstract

Antiviral agents are urgently needed to fight severe acute respiratory syndrome (SARS). We showed that niclosamide, an existing antihelminthic drug, was able to inhibit replication of a newly discovered coronavirus, SARS-CoV; viral antigen synthesis was totally abolished at a niclosamide concentration of 1.56 microM, as revealed by immunoblot analysis. Thus, niclosamide represents a promising drug candidate for the effective treatment of SARS-CoV infection.

• Authors: Chang-Jer Wu, Jia-Tsrong Jan, Chi-Min Chen, Hsing-Pang Hsieh, Der-Ren Hwang, Hwan-Wun Liu, Chiu-Yi Liu, Hui-Wen Huang, Su-Chin Chen, Cheng-Fong Hong, Ren-Kuo Lin, Yu-Sheng Chao, John T A Hsu
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 48 Issue 7 Pg. 2693-6 (Jul 2004) ISSN: 0066-4804 [Print] United States
• PMID: 15215127 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anthelmintics
• Antiviral Agents
• Niclosamide

Topics

• Animals
• Anthelmintics (pharmacology)
• Antiviral Agents
• Chlorocebus aethiops
• Fluorescent Antibody Technique
• Niclosamide (pharmacology)
• Severe acute respiratory syndrome-related coronavirus (drug effects)
• Vero Cells
• Virus Replication (drug effects)